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Abstract
Objective—Family and twin studies suggest that liability for suicide attempts is heritable and
distinct from mood disorder susceptibility. The authors therefore examined the association
between common genomewide variation and lifetime suicide attempts.
Method—The authors analyzed data on lifetime suicide attempts from genomewide association
studies of bipolar I and II disorder as well as major depressive disorder. Bipolar disorder subjects
were drawn from the Systematic Treatment Enhancement Program for Bipolar Disorder cohort,
the Wellcome Trust Case Control Consortium bipolar cohort, and the University College London
cohort. Replication was pursued in the NIMH Genetic Association Information Network bipolar
disorder project and a German clinical cohort. Depression subjects were drawn from the
Sequential Treatment Alternatives to Relieve Depression cohort, with replication in the
Netherlands Study of Depression and Anxiety/Netherlands Twin Register depression cohort.
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Results—Strongest evidence of association for suicide attempt in bipolar disorder was observed
in a region without identified genes (rs1466846); five loci also showed suggestive evidence of
association. In major depression, strongest evidence of association was observed for a single
nucleotide polymorphism in ABI3BP, with six loci also showing suggestive association.
Replication cohorts did not provide further support for these loci. However, meta-analysis
incorporating approximately 8,700 mood disorder subjects identified four additional regions that
met the threshold for suggestive association, including the locus containing the gene coding for
protein kinase C-epsilon, previously implicated in models of mood and anxiety.
Conclusions—The results suggest that inherited risk for suicide among mood disorder patients
is unlikely to be the result of individual common variants of large effect. They nonetheless provide
suggestive evidence for multiple loci, which merit further investigation.
Epidemiologic studies indicate that mood disorders are associated with a marked increase in
risk for suicide and suicide attempts, with one such study suggesting a 20-fold greater risk of
death from suicide compared with the general population (1). The familiality of suicide risk
is well-established (for a review, see Brodsky et al. [2]) and not accounted for solely by
familial transmission of mood disorders (3–5). For example, a family-based study of a large,
bipolar disorder cohort suggested that lifetime suicide attempts were among the more
strongly familial features of the disorder (6). That risk for suicide attempt in particular is
heritable is supported by twin studies (7, 8), with heritability estimates ranging from 30%–
50%, intermediate between major depressive disorder and bipolar disorder. Adoption studies
suggest that this risk cannot be explained solely by shared environment (9).
Individual candidate-gene studies have implicated genes of the serotonergic or
noradrenergic system (10–14), hypothalamic-pituitary-adrenal axis (15,16), renin-
angiotensin system (17), and neuronal development (18–20) and function (21) in the
propensity for suicide, using a variety of case and control definitions (for a review, see
Brezo et al. [22]). However, given the limited understanding of pathophysiology, prioritizing
candidates for study has been difficult and likely accounts for the near absence of consistent
replication. The emergence of low-cost approaches for characterizing common genetic
variation across the genome facilitates an alternate approach, which may lead to
identification of truly novel risk factors, as has been the case in nonpsychiatric disorders
(23).
Therefore, we analyzed data from multiple genomewide association studies to identify
variations associated with suicide risk. To minimize the potential heterogeneity introduced
by pooling mood disorder subjects, cohorts with bipolar disorder and major depression were
examined separately and then combined for meta-analysis. In all, data from >8,700 mood
disorder subjects were used to detect and replicate associations.
Method
Study Design, Genotyping, Quality Control, and Imputation
The cohorts examined in the present study are summarized in Table 1. For bipolar disorder,
genomewide association data were derived from three nonoverlapping cohorts of bipolar I or
II patients, all of which were included in a previously reported meta-analysis of disease
liability (24). These bipolar disorder cohorts were from the Systematic Treatment
Enhancement Program for Bipolar Disorder (STEP-BD) (25, 26), the Wellcome Trust Case
Control Consortium (27), and the University College London. Details of sample
ascertainment and genotyping have been previously described by Ferreira et al. (24). Quality
control and imputation using MACH (28) are described in the original reports (summarized
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in the data supplement accompanying the online version of this article), yielding 1,922,309
single nucleotide polymorphisms (SNPs) in 3,117 subjects.
Follow-up analyses examined the most significant SNPs from these cohorts in pooled data
from the following three additional bipolar disorder cohorts: the initial Genetic Association
Information Network (GAIN) bipolar disorder project and the Translational Genomics
Research Institute samples (29), both drawn from the five waves of sample collection in the
NIMH Bipolar Disorder Genetics Initiative (30), and a sample of German individuals
collected at the Universities of Bonn and Heidelberg (31). Genotyping, quality control, and
imputation are described by Smith et al. (29) and McMahon et al. (31).
Table 1 also lists the major depression cohorts included in primary and replication analyses,
which were the Systematic Treatment Alternatives to Relieve Depression (STAR*D) cohort
(32) and the GAIN depression cohort that was derived from the Netherlands Study of
Depression and Anxiety (33)/Netherlands Twin Register (34) cohorts (35). The former data
set was used in initial analyses, with replication pursued in the latter. Details of genotyping
and quality control for the STAR*D cohort have been previously described by Garriock et
al. (36) (for additional quality control steps and imputation using MACH, see the data
supplement), yielding 1,954,455 SNPs in 1,273 subjects. For the Netherlands Study of
Depression and Anxiety/Netherlands Twin Register, methods are described by Sullivan et al.
(35). Imputation was performed using IMPUTE (http://mathgen.stats.ox.ac.uk/impute/
impute.html), with a threshold of 70% confidence.
Identification of Lifetime Suicide Attempts
For the STEP-BD cohort, determination of lifetime suicide attempts was conducted using all
available sources of information, including the Affective Disorders Evaluation (37), which
incorporates questions from the Structured Clinical Interview for DSM-IV Axis I Disorders
(38) at study entry, as well as data regarding suicide attempt during the study period
documented as serious adverse effect or hospitalization. In the Wellcome Trust Case Control
Consortium, lifetime suicide attempts were identified with a semistructured diagnostic
psychiatric interview. Assessment of the University College London cohort was conducted
utilizing the Schedule for Affective Disorders and Schizophrenia–Lifetime version (39),
which includes questions about the presence or absence of lifetime suicide attempt. Among
the replication cohorts, the GAIN and Translational Genomics Research Institute samples
were assessed using the Diagnostic Interview for Genetic Studies (40), which includes
questions regarding lifetime suicide attempt. Assessment of the German university cohorts
also incorporated structured interview and review of psychiatric history.
In the STAR*D cohort, lifetime history of suicide attempts was assessed at the initial study
visit by the study clinician (41); suicidality was not exclusionary, provided the patient did
not require hospitalization for stabilization. Finally, lifetime suicide attempt in the
Netherlands Study of Depression and Anxiety/Netherlands Twin Register group was
determined at diagnostic interview, which included the Composite International Diagnostic
Interview, version 2.1 (42).
Analysis
Primary analyses were performed with logistic regression of the presence or absence of
suicide attempt on single SNP allelic dosage, adjusted for the first four components from the
aforementioned multidimensional scaling plot, to address the possibility of confounding by
population substructure. Analyses were conducted using PLINK, version 1.07 (43). Results
were not meaningfully different with inclusion of the first 10 indices of ancestry.
Perlis et al. Page 3













The bipolar disorder and major depression cohorts were initially analyzed independently as
discovery data sets, based on the hypothesis that suicide susceptibility could be diagnosis-
specific so that pooling across mood disorders would increase heterogeneity and diminish
power to detect association. All available data sets were initially pooled, rather than holding
some out to allow for a replication cohort. Therefore, to examine suicide liability among
patients diagnosed with bipolar disorder, combined data from the STEP-BD, Wellcome
Trust Case Control Consortium, and University College London cohorts were analyzed
jointly. For replication, any SNP with a p value <1×10−3 in this combined cohort was then
examined in the combined GAIN, Translational Genomics Research Institute, and German
cohorts. In parallel, STAR*D data were analyzed for association with suicide attempts
among individuals with major depression. For replication, any SNP associated with a p
value <1×10−3 was then examined in the Netherlands Study of Depression and Anxiety/
Netherlands Twin Register cohorts. Power to detect association at the nominal threshold for
replication (p<1×10−3) in the bipolar discovery cohort was >95% for a minor allele
frequency of 20% and genotypic risk ratio of 1.25, corresponding to a genotypic odds ratio
of approximately 1.36. For depression, power under the same conditions decreased to 33%.
Finally, to examine the hypothesis that suicide liability arises from variation common to
depression and bipolar disorder, random effects meta-analysis was used to examine any SNP
implicated in either bipolar disorder or depression with a p value <1×10−3 across all mood
disorder subjects, using PLINK. For the combined cohorts, power was >90% to detect
association at a p value <5×10−8 for a minor allele frequency of 20% and genotypic risk
ratio of 1.2, which in the present study corresponds to a genotypic odds ratio of
approximately 1.3.
For descriptive purposes, a set of candidate genes was identified based upon previous
reports of association. Candidates were selected based on a MEDLINE search, performed in
June 2010, using the terms “suicide,” “genetic,” and “association,” followed by manual
review of abstracts under the name of the corresponding author of the articles identified.
Any gene with at least one report of significant association with suicide attempt was
included, even if such association was identified only in a subset of subjects. This search
yielded 19 regions. We performed gene-based tests by combining the single-SNP p values,
using a weighted-inverse chi-square method that accounts for correlation between tests (44),
implemented in PLINK. We used the correlation between alleles (i.e., linkage
disequilibrium) in the Caucasian-European (Centre d’Etude du Polymorphisme Humain
from Utah) phase II HapMap project to estimate the correlation between tests, which
performed well in simulation experiments. For descriptive purposes, the minimum p value
for any SNP within the gene or 20-kb flanking regions was also identified.
Results
In the bipolar disorder cohort, 1,295 out of 3,117 subjects (41.5%) reported a history of
suicide attempts. Figures 1 and 2 in the data supplement show Q-Q and Manhattan plots for
suicide attempts in this cohort (λ=1.003). A total of five loci included SNPs with a p value
<1×10−5; the minimum p value was 1.98×10−6 (rs1466846, with no known gene within 400
kb) (Table 2 [also see Table 1 in the data supplement]). None of these loci yielded a nominal
p value <0.05 in the bipolar disorder replication cohort, which included 2,698 subjects, of
whom 1,201 (44.5%) reported a lifetime history of suicide attempts.
Among 1,273 subjects with major depression, 176 (9.9%) reported a history of suicide
attempts. Q-Q and Manhattan plots for this cohort are presented in Figure 3 and Figure 4 in
the data supplement (λ=1.017). A total of six loci included SNPs with a p value <1×10−5;
the minimum p value was 2.55×10−8 (rs2576377 in gene ABI3BP) (Table 3 [also see Table
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2 in the data supplement]). However, none of these regions yielded a p value <0.05 in a
second depression cohort of 1,649 subjects, including 133 individuals (8.1%) with a history
of suicide attempts.
We also examined association results in 19 genes previously suggested to be associated with
suicide attempts in at least one prior report. Table 4 lists the results of a gene-based test for
association, which accounts for correlation between tests (SNPs) within a gene. Two genes,
FKBP5 and NGFR (p75NTR), showed nominal evidence of association in bipolar disorder
subjects (uncorrected p<0.05) but did not survive correction for 19 comparisons (see Table 4
in the data supplement). Minimum single-SNP p values for each gene (with 20-kb flanking
regions) are presented in the data supplement.
Lastly, we examined any SNP with a p value <1×10−3 in either the major depression or
bipolar disorder discovery cohort, using random-effects meta-analysis across all available
mood disorder subjects (N=8,737). None of the aforementioned loci identified were more
strongly implicated by meta-analysis. Table 5 shows all SNPs with a p value <1×10−5 in the
overall meta-analysis (complete results are shown in Table 3 of the data supplement). The
10 SNPs that met this threshold are in four loci, including SNPs in genes coding for sorbin
and SH3-domain containing-1 (SORBS1) and protein kinase C-epsilon (PRKCE).
Discussion
We examined and then attempted to replicate associations with suicide attempt liability
among a total of approximately 2,900 subjects with major depression and approximately
5,800 subjects with bipolar disorder. One region, with multiple intronic SNPs in Abl-
interactor family member 3 binding protein (ABI3BP or TARSH) (45), met our threshold
for genomewide significance in suicide attempt liability among individuals with depression
but failed to replicate in a second cohort. This gene is known to be expressed in brain as well
as multiple other organ systems, but its function is not well-characterized, although it may
have effects in apoptosis and senescence (46–48). While the most likely explanation for this
nonreplication remains a type I error, we also note that heterogeneity between STAR*D and
the Netherlands Study of Depression and Anxiety/Netherlands Twin Register has been
suggested as another explanation for nonreplication of significant associations with variants
in the Piccolo (PCLO) region in depression liability (35). Other regions with suggestive
evidence of association in depression include SLC4A4, coding for a sodium bicarbonate
cotransporter, which is also widely expressed (and believed to interact with inositol
triphosphate signaling [49]); hyaluronan synthase-1 (HAS1), important in synthesis of
extracellular matrix and brain inflammatory response (50, 51); adenosine
diphosphateribosylation factor-like-6-interacting protein-2 (ARL6IP2), whose expression is
influenced by nitric oxide signaling (52); and the putative leucinerich repeat-containing
protein 44 (LRRC44 or LRRIQ3) (53).
Among the most regions with the greatest evidence of association in bipolar disorder were
the transducin beta-like receptor 1 (TBL1XR1), implicated in gene activation by nuclear
receptors (for example, based upon presence in histone deacetylase-3 (HDAC3) complexes
[54]); Iroquois homeobox protein 2 (IRX2), important in embryonic pattern formation,
including brain development (55); and calpain-13 (CAPN13), part of a class of cysteine
proteases with multiple functions, including synaptic plasticity (56). Once again, no single
SNP showed evidence of replication in a second cohort. Examination of candidate regions
using a gene-based test provided modest support for two loci, FKBP5 and NGFR (p75NTR),
identified in previous investigations of suicide attempt (19, 20), although neither results
survived correction for the 19 tests performed.
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Meta-analysis of association data across mood disorders did not provide further support for
the novel loci identified in the discovery cohorts. However, SNPs in two genes were
associated with a p value <1×10−5. The first, SORBS1, has been implicated in insulin
signaling (57); its product was also shown to interact with ataxin-7, the site of a trinucleotide
repeat causing spinocerebellar atrophy type 7 (58). The second, PRKCE, is most notable
because PRKCE null mice have been shown to exhibit reduced anxiety behavior and lower
levels of multiple stress hormones, with increased sensitivity to neurosteroids that modulate
gamma-aminobutyric acid type A receptors (59). A recent postmortem study found
differences in expression of multiple protein kinases, including PRKCE, in individuals with
depression relative to comparison subjects (60). Overall, this examination of approximately
8,700 mood disorder subjects may provide a framework for considering future association
results.
While our results provide some support for multiple novel regions of potential interest, they
also suggest that individual common variants of large effect are unlikely to account for the
known heritability of suicide risk, leading to the problem of missing heritability. A recent
review described multiple potential explanations for the observed paucity of common
variants of large effect, noting the potential importance of epistatic or epigenetic effects, for
example, among many others (61). Notably, the absence of large effects also does not
preclude SNPs in aggregate accounting for a substantial proportion of disease risk, which
may be the case in schizophrenia, for example (62). However, it also bears consideration
that suicide liability should detract from reproductive fitness, with the pressure of purifying
selection acting to keep risk variants rare, which might argue for more aggressive pursuit of
rare variants (61).
Several features of our analytic approach bear consideration. We prioritized a within-
disorder analysis to minimize the potential heterogeneity introduced by combining mood
disorder subjects in the absence of strong evidence of cross-disorder risk. Pooling both
disorders could have improved our power to detect association but at the cost of reducing
power because of heterogeneity. Similarly, while we initially analyzed all samples available
to us (rather than holding some out in order to allow for replication), we were later able to
identify replication data sets, but not to fully pool results. Thus, the final design included
discovery followed by replication. We pursued a replication-discovery design.
We elected to assess the harder endpoint of suicide attempt rather than lifetime suicidal
ideation for two reasons. First, the latter is difficult to assess retrospectively, while recall and
other biases are less likely to impact reporting of suicide attempt, particularly where sources
of collateral information, such as emergency room visits or hospital discharge summaries,
are available. Retrospective suicidal ideation was not assessed in STEP-BD or STAR-D.
Second, twin studies suggest that while much of the heritability of thoughts of suicide may
be accounted for by familial transmission of disease liability, risk for suicidal behavior may
be more distinctly heritable (2). An important caveat in considering these results is that
lifetime suicide attempt was not the primary phenotype of interest in these cohorts and was
assessed by one or a few items on a scale. Thus, it is likely that suicide attempt was
underreported in these cohorts, which would lead to misclassification error and diminish our
power to detect association. In addition, while many mood disorder subjects make a suicide
attempt early in their illness course, we cannot exclude the possibility that some subjects
labeled as nonattempters would ultimately go on to make an attempt, leading to further
misclassification.
Also of note, to minimize type I error, we did not consider any subphenotypes.
Investigations of suicide often focus on the nature of the suicide attempt, in terms of degree
of aggression or violence involved; more violent or more potentially lethal attempts have
Perlis et al. Page 6













been suggested to represent a subgroup with greater homogeneity (63). However, the
majority of cohorts examined in the present study did not distinguish this phenotype. We
also did not conduct sex-stratified analyses. While suicidal behavior may differ by sex, we
could not identify a strong rationale for positing sex differences in heritability and were
mindful of the hazards of this sort of subanalysis (64).
Some prior investigations of suicide have compared suicide attempters with healthy
comparison subjects. In the present study, we elected instead to contrast attempters with
nonattempters among a single disorder, which allowed us to distinguish genes conferring
suicide risk beyond that conferred by the disorder itself. That is, rather than a case-control
association study of the putative subtype of bipolar-plus-suicide attempt, we focused on
suicide liability per se.
Taken together, our results suggest an absence of common variants of large effect mediating
suicide liability in mood disorders. A recent investigation of bipolar disorder and
schizophrenia liability suggested that a substantial portion of risk for these disorders may be
highly polygenic (62). The observation of an excess of SNPs with p values approximately
≥1×10−3, apparent in both Q-Q plots but particularly in that of the depression cohort, would
be consistent with this model. For the effect sizes observed in our meta-analysis (i.e., odds
ratio of approximately 1.2), approximately 7,000 suicide attempt cases (with matched
nonattempting comparison subjects) would be required for 80% power to identify SNPs with
a minor allele frequency of 20% and a p value <5×10−8. Thus, analysis of even larger
cohorts, in the context of consortia such as the Psychiatric Genomewide Association Study
Consortium (65), and consideration of alternate models of heritability—for example, using
polygenic models or considering rarer variants of larger effect—may be required to identify
loci that confer risk for suicide in mood disorders.
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TABLE 1
Mood Disorder Cohorts Included in Suicide Attempt Analyses
Suicide Attempt
Disorder Cohort Study Cohort N N %
Bipolar disorder
Discovery STEP-BD; Wellcome Trust Case Control Consortium; University College London 3,117 1,295 41.5
Replication
GAIN bipolar disorder project; Translational Genomics Research Institute;
Universities of Bonn/Heidelberg 2,698 1,201 44.5
Major depressive disorder
Discovery STAR*D Caucasian 1,273 176 9.9
Replication Netherlands Study of Depression and Anxiety/Netherlands Twin Register 1,649 133 8.1
Combined 8,737 2,805 32.1
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TABLE 4
Gene-Based Tests of Association for 19 Candidate Loci
Bipolar Disorder Major Depression
Gene Single Nucleotide Polymorphisms Gene (p) Single Nucleotide Polymorphisms Gene (p)
ACE 11 0.30 21 0.38
ADRA2A 10 0.81 16 0.44
AKT1 9 0.81 11 0.57
COMT 48 0.18 43 0.62
CRHBP 20 0.15 18 0.18
CRHR1 66 0.38 65 0.41
CRHR2 26 0.37 26 0.48
DRD2 92 0.71 98 0.67
FKBP5 41 0.04 41 0.20
HTR1A 12 0.09 12 0.88
HTR2A 120 0.29 122 0.47
LSAMP 417 0.06 414 0.82
NGFR 12 0.03 12 0.65
NOS1 111 0.17 113 0.54
NTRK2 316 0.85 341 0.47
SLC6A4 37 0.09 36 0.06
TAAR6 65 0.72 64 0.71
TPH1 40 0.28 40 0.37
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